Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Small single-center matched cohort study (31 per group) with retrospective design and surrogate endpoints; findings on concurrent nephropathy and renal function decline are clinically relevant but require validation in larger prospective studies.
This is an ongoing observational registry study with no reported results; it documents planned genetic and phenotypic characterization of BHD syndrome and kidney cancer risk, but outcomes remain incomplete.
Preclinical evidence in a mouse model demonstrates that a sequenced triple regimen achieves high complete response rates, but findings are not yet clinically validated and lack quantitative efficacy metrics in the abstract.